Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Year: 2020
Type: review
Abstract: Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection.
DOI: 10.17615/3w2y-ap42
Authors: Segal, Jodi B., Nelson, David R., Falade-Nwulia, Oluwaseun, Sulkowski, Mark S., Fried, Michael W., Suarez-Cuervo, Catalina
Institution: University of North Carolina at Chapel Hill
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4301045216